Intermittent claudication is usually due to atherosclerotic plaque which induces a haemodynamically significant lesion of the aorto-iliac, femoral, popliteal or infrapopliteal vessels. Careful history-taking and physical examination allow the physician to distinguish between this entity and other disorders associated with painful ambulation. Most of these patients can be managed with conservative medical therapy, with rigorous attention to the prevention of complications and the reduction of risk factors which are responsible for progression of the disease. This article will review the natural history of patients with intermittent claudication, discuss clinical evaluation and propose a strategy for medical management.
Incidence and natural history
Atherosclerosis is the leading cause of occlusive arterial disease of the extremities. The prevalence of symptomatic disease increases with age, affecting approximately 60/1000 men and 20/1000 women in the population aged 60 and over. 1, 2 The disorder is more common in those who use tobacco and those who have elevated serum cholesterol or glucose, elevated blood pressure or a family history of premature arterial occlusive disease. Only in a minority of patients is there no apparent risk factor, and uncommon aetiologies of arterial occlusive disease should be considered in these cases ( Table 1 ). The use of tobacco, specifically cigarettes, is the risk factor which is most highly correlated with the occurrence of intermittent claudication. 3, 4 In the Framingham study the rate of occurrence of intermittent claudication was doubled in smokers and tended to increase with the intensity of the habit.s The Framingham study also revealed that multiple risk factors act synergistically, rather than additively, increasing the incidence of stroke or myocardial infarction dramatically. It is for this reason that risk factor reduction is so important in the care of these patients.
The symptoms of intermittent claudication remain stable over time in the great majority of patients, particularly in those who reduce their risk factors. In a study from the Mayo Clinic, approximately 90% of patients (with superficial femoral artery disease and without diabetes mellitus) had no progression of symptoms or improved,6 while other investigators have reported that 80% of patients will have no progression of their symptoms over a period of 2.5 years.7 However, the natural history of the disease is different for patients with diabetes mellitus, or for patients who continue to smoke: the amputation rate in diabetics is four times higher than for nondiabetics over a period of five years,6 and smokers also have an increased incidence of limb loss, although the prognosis improves if the use of tobacco is discontinued. In one study of smokers with arterial occlusive disease, 11 % of patients who continued to smoke eventually underwent amputation after five years; no limb loss occurred over the same time period in those who stopped smoking.8 The prognosis is also worse for those patients who first present with ischaemic rest pain and ulceration: 20% of this group will eventually undergo amputation. In those patients with intermittent claudication due to thrombo-angiitis obliterans the only effective therapy is to discontinue the use of tobacco: 50% of such patients will undergo amputation of an extremity if they do not stop smoking, whereas only 4% of those who do stop smoking will suffer recurrences or complications.9 9 Although intermittent claudication in most patients tends to be stable over time, this disorder is not benign. Over a period of 14 years in the Framingham study the average annual mortality for men with intermittent claudication was 39/1000 compared to 10/1000 males without the disease.10 The overall life expectancy over a ten-year period is reduced; survival rates are approximately 70-80% for five years, 40% for ten years and only 26% for 15 years. The majority of the deaths are due to ischaemic heart disease.
The increased incidence of coronary artery heart disease in these patients has been documented by careful angiographic studies from the Cleveland Clinic in which over 90% of patients considered for vascular surgery had angiographic evidence of coronary artery disease.ll Even in those patients who are asymptomatic from myocardial ischaemia, the incidence of significant and surgically correctable coronary artery disease is considerable.
Clinical evaluation
Patients most commonly describe an aching discomfort or a fatigue of the legs precipitated by exertion and relieved by standing still. The location of the discomfort depends upon the location of the significant lesions: with infrapopliteal artery disease the patient may develop discomfort only in the soles of the feet; with superficial femoral artery disease the patient will describe a discomfort in the calves; and with aortoiliac disease the discomfort will also be felt in the hips, thighs and buttocks. The amount of exertion required to precipitate symptoms is usually quite constant from one day to the next, and the patient usually gives a reliable estimate as to the walking distance required to induce symptoms. Symptoms are precipitated earlier if the pace is quickened, if the patient is carrying additional weight (such as a bag of groceries) or if a steep hill or a flight of stairs is encountered. Occasionally, symptoms will worsen precipitously due to thrombosis in situ (e.g. due to rupture of an atherosclerotic plaque or thrombosis of collaterals) or due to embolism (e.g. athero-embolism or dislodgement of mural thrombus from a diseased aorta).
Careful history-taking will also differentiate intermittent claudication from other causes of painful ambulation. Pseudoclaudication due to spinal stenosis is the disorder most commonly confused with intermittent claudication. The patient with pseudoclaudication also develops an aching discomfort or fatigue in the lower extremities with ambulation. However, these symptoms are not completely relieved by standing still and the subject needs to sit down or to become supine to gain relief. Standing for prolonged periods can precipitate symptoms in the patient with pseudoclaudication but not in the patient with symptoms due to arterial occlusive disease; moreover, the former group of patients will often note low back pain. The leg discomfort may have a dysesthetic quality or there may be a history of paresthesia and/or ataxia of gait. Walking down a flight of stairs may be as difficult as walking up. The diagnosis of pseudoclaudication is confirmed by computerized tomography of the spine, which reveals impingement upon the spinal canal, normally due to degenerative disease. Ancillary tests include electromyography (to demonstrate evidence of denervation) and noninvasive vascular tests (to confirm that symptoms are out of proportion to the vascular disease detected, if any). Mechanical derangements of the hip or knee can also induce painful ambulation, but it is less problematic to differentiate this from symptomatic arterial occlusive disease. Discomfort usually begins immediately with walking or with weight-bearing and ceases just as quickly when weight-bearing ceases. It is generally localized to the joint, and there is often a history of arthralgias or arthritis.
A meticulous history will include a careful survey for symptoms of arterial occlusive disease in other circulations. One should specifically question the patient about symptoms of myocardial and cerebrovascular ischaemia as well as for the existence of the associated medical disorders of hypertension, hypercholesterolaemia, diabetes mellitus and tobacco use. A family history of premature arterial occlusive disease may signal the existence of other medical disorders predisposing to The femoral pulse is attenuated in the presence of significant iliofemoral disease. The popliteal pulse is the most difficult to palpate, but can be appreciated in the majority of normal individuals with practice. Its absence signifies superficial femoral artery occlusion or high-grade stenosis. One should not miss the opportunity to detect a popliteal aneurysm since these can be associated with dramatic thrombo-embolic complications in the lower extremity. Moreover, since 30-60% of these patients will have an abdominal aortic aneurysm, this finding should also initiate further work-up for aortic disease. [14] [15] [16] In approximately 5% of normal subjects, the dorsalis pedis pulse is congenitally absent -this condition is invariably bilateral.17 Absence of a posterior tibial artery, on the other hand, is rarely congenital and is usually due to arterial occlusive disease. In the upper extremities the brachial, radial and ulnar pulses should be palpated; the ulnar artery is often difficult to detect in normal individuals. The presence of a patent ulnar artery may be confirmed by an Allen's test.
Depending upon the extent to which collateral vessels have formed, diminished pulses in the lower extremities may or may not be associated with significant ischaemia. Patients occasionally present with only mild intermittent claudication but with no palpable pulse in either lower extremity ; such patients probably have longstanding aortic occlusion and have developed collaterals. To determine the severity of ischaemia, the clinician must search for elevation pallor and dependent rubor and quantitate the venous filling time. Elevation pallor is determined by raising the legs to a 30° angle: if pallor develops within 60 seconds the patient has mild ischaemia; within 30 seconds, moderate ischaemia; and within 15 seconds, severe ischaemia. The extremity is in jeopardy if pallor is already present with the leg in a level position. The legs are then lowered and the patient sits up with the legs in a dependent position. The superficial veins on the dorsum of the foot fill within 15 seconds in normal individuals: a filling time of greater than 15 seconds indicates mild ischaemia; greater than 30 seconds indicates moderate ischaemia; and greater than 45 seconds indicates severe ischaemia. Dependent rubor will also be noted in patients with arterial occlusive disease with the legs in a dependent position. In patients with longstanding and significant arterial occlusive disease of the lower extremities, trophic changes in the legs are noted such as atrophy, thin and 'shiny' skin, hair loss and dystrophic nail changes. Ischaemic ulcers may be noted, usually at pressure points such as the malleolus, over the interphalangeal joints or in the web space between the toes. The ischaemic ulcer may be differentiated from other ulcers in that it has a thick black eschar, usually round with well demarcated edges which are painful to the touch; when the ischar is removed, a pale base is revealed with poor granulation tissue that bleeds little.
Occasionally the patient's symptoms may be acutely exacerbated by an athero-embolic event from a proximal vessel, usually the aorta -in these cases evidence of athero-emboli may be noted. Livedo reticularis may be noted on the buttocks, thighs or feet, and several of the toes may be cyanotic.
Additional information may be obtained in the office using a hand-held Doppler device. A careful Doppler examination takes only a few minutes and significantly supplements the physical examination. One may listen over the posterior tibial and dorsalis pedis arteries for a Doppler signal. The signal is normally strong and biphasic or even triphasic in young individuals; with arterial occlusive disease the signal becomes diminished and monophasic; with severe disease the signal is faint and monophasic or absent. A blood pressure cuff is then applied above the ankle and the cuff pressure increased to suprasystolic level. As the pressure in the cuff is released one listens over the dorsalis pedis pulse for the return of the signal and notes the pressure at which this occurs; this procedure is repeated at the level of the posterior tibial artery and blood pressure in the upper extremity is taken simultaneously. One can then calculate an ankle-brachial index (i.e. the ratio of ankle to brachial artery pressure), which correlates with the severity of the ischaemia (Table 2) . Table 2 The ankle-brachial index (ABI) ABI = brachial systolic pressure/ankle systolic pressure Noninvasive laboratory assessment of arterial occlusive disease
The seasoned clinician can usually make the diagnosis of intermittent claudication without any further testing. Noninvasive laboratory testing is normally used to quantitate the degree of disease and is particularly useful for postoperative follow-up; it is helpful occasionally in complex cases in which both pseudo-and intermittent claudication appear to be present. These noninvasive laboratory tests include pulse volume recordings, Doppler velocity analysis, segmental pressure measurements and ankle brachial indices following treadmill exercise testing. Pulse volume recordings provide a qualitative analysis of the severity of disease: as the arterial occlusive disease progresses, the amplitude of the pulse volume is attenuated and the contour becomes less distinct (the dicrotic notch is obliterated). Pulse volume recordings are usually combined with segmental pressure measurements (which are a more quantitative index). Blood pressure cuffs are placed at the thigh, above the knee, below the knee and at the ankle so as to detect pressure gradients occurring at the iliofemoral, superficial femoral, popliteal and infrapopliteal levels respectively; a reduction in pressure of greater than 15% from one level to the next is generally predictive of a haemodynamically significant lesion at that level. Segmental pressure measurements are a good barometer of the severity of occlusive disease, although they become unreliable in patients with extensive and circumferential vascular calcification. Calcified vessels are relatively noncompressible and the cuff pressure required to occlude these vessels greatly overestimates the true intra-arterial pressure. Pulse volume recordings are more accurate indicators of blood flow in such patients.
Treadmill exercise testing is a valuable adjunct to the clinical evaluation. This test ideally combines the measurement of ankle brachial indices before and after exercise with continuous electrocardiographic monitoring during exercise and recovery in order to assess for myocardial ischaemia and/or arrhythmia. A standard Bruce protocol may occasionally be employed, but a modified Bruce protocol is optimal in most patients with intermittent claudication. The electrocardiogram, blood pressure, heart rate and symptoms are monitored during exercise and periodically in the recovery period until these parameters return to baseline values. The ankle brachial indices are measured immediately before and after exercise and are followed at three-minute intervals until the ankle brachial index has returned to the baseline value. This test gives valuable information regarding associated coronary artery disease and the functional limitation of the patient, as well as the severity of peripheral disease. This test is not usually necessary to make the diagnosis of intermittent claudication, but can be helpful in determining the contribution of occlusive arterial disease to the patient's symptoms when there is coexistent spinal stenosis. Occasionally one may see a patient with a history of mild to moderate claudication but with a relatively normal exam and resting segmental pressure measurements and pulse volume recordings. Such a patient is likely to have a haemodynamically significant iliac stenosis and will develop a detectable pressure gradient during exercise.
Transcutaneous oximetry and laser Doppler velocimetry are two new methods for assessing perfusion. Duplex ultrasonography is helpful in locating and quantitating the severity of occlusions in the conduit vessels and is now used routinely to follow the progression of disease in native vessels and in bypass grafts -it is also useful in preoperative evaluation of the saphenous vein prior to in situ bypass grafting.
Medical management
General measures General supportive measures and reduction of risk factors for progression of disease are the mainstays of conservative medical management; conversely, pharmacotherapy to improve blood flow directly, has met with disappointing results. One of the most important measures is to protect the feet from trauma, as over 60% of amputations are secondary to infection and eventual gangrene originally proceeding from preventable thermal, chemical or physical trauma Common forms of trauma include pressure necrosis due to poorly fitting shoes, inadvertent trauma during nailtrimming leading to cellulitis and gangrene, and pressure necrosis induced by one toe impinging upon its neighbouring digit. For these reasons it is useful to enlist the aid of a podiatrist for the selection of appropriate footwear and expert nail-trimming. Pressure necrosis of neighbouring digits can be prevented by the insertion of a wedge of lamb's wool. It should be explained to the patient that, with reduced perfusion, trauma will heal slowly, if at all, and that meticulous hygiene is essential. The feet should be kept clean and dry and protected from trauma at all times; the luxury of walking about in bare feet is one which the patient can ill afford. The skin should be kept hydrated with an emollient so as to prevent drying of the skin and subsequent fissuring, which can provide a portal of entry for infectious agents.
When the patient is carrying excess weight or quickens pace, the skeletal muscles' oxygen demand exceeds the supply more rapidly. Patients can modify their work habits so as to ambulate longer without stopping. The pace can be slowed or objects that are normally carried (such as a toolbelt or a mailbag) can be pushed in a cart. If a patient is obese, walking distance can be increased considerably by weight loss.
Exercise rehabilitation
With a good exercise programme, patients are able to increase their pain-free walking distance by approximately 85%significant improvement usually seen within three months. [19] [20] [21] [22] [23] We generally recommend that patients walk for 30-60 minutes daily, stopping periodically during that time when they develop symptoms; they resume walking as soon as their symptoms resolve. In most patients one should perform a treadmill exercise test prior to prescribing an exercise regimen so as to rule out significant exercise-induced myocar-dial ischaemia. The mechanism by which exercise improves walking distance is not yet understood: in some patients there is an improvement in reactive hyperaemia, suggesting that blood flow to the extremity has been improved, possibly through the formation or enlargement of collateral vessels, although in most patients the improvement is probably due to other mechanisms such as an increase in the efficiency of uptake or utilization of oxygen and nutrients. 24 According to the Framingham study smokers are at twice the risk of developing intermittent claudication; indeed, 70-90% of patients with intermittent claudication are smokers.5 Atherosclerosis is more likely to progress in smokers, and limb-threatening ischaemia and amputation and more common outcomes. 4,25-28 Bypass grafts are also more likely to fail: in one study, the fiveyear cumulative patency rates for aortofemoral and femoropopliteal bypass grafts were 90% and 80% respectively compared to only 30% and 45% for patients smoking more than five cigarettes daily.25 The discontinuance of this habit will not immediately improve symptoms, but it should be explained to the patient that the risk of complications or progression of the disease will be reduced.
In the absence of diabetes mellitus, the disease rarely progresses to amputation in nonsmokers. 6 In addition to strongly advising the patient to abandon the use of tobacco, the physician should consider supportive counselling and the use of nicotine chewing-gum. Placebo-controlled studies have demonstrated that such a programme increases the rate of smoking cessation29,30 and the addition of nicotine chewing-gum to the physician's counsel increases success rates by 30%.3i
Treatment of hypercholesterolaemia Hypercholesterolaemia is another risk factor which should be aggressively treated. A large number of animal and human studies have revealed that hypercholesterolaemia induces a dysfunction of the endothelial lining of the blood vessel which may be the primary event in atherosclerosis. [32] [33] [34] [35] [36] [37] [38] The endothelium produces a number of substances which induce vasodilation, inhibit adhesion and aggregation of platelets or other blood elements and suppress proliferation of vascular smooth muscle.39-42 The synthesis and/or release of at least two of these substances, endothelium-derived relaxing factor and prostacyclin, are reduced by elevated levels of cholestero1.32-3s>43 A reduction in these protective factors and an increase in the production of mitogenic substances may be primary events leading to atherosclerosis in hypercholesterolaemic animals and man. It is now known that reduction of cholesterol in experimental animal models improves endothelial function and prevents the progression, or even induces the regression, of atherosclerotic lesions. 44, 45 There is only a limited amount of information from clinical trials, but this together with experimental data suggest that aggressive treatment of hypercholesterolaemia is justified. In one study, Blankenhorn et al. analysed atherosclerotic lesions of the femoral arteries in patients employing digital subtraction angiography. 46 The studies were repeated after one year of intensive antilipid therapy: progression occurred in only half the patients, while regression was noted in a third of the patients. Serum cholesterol levels were significantly lower in those patients in whom the lesions regressed.
These results confirm other studies which have demonstrated that treatment of hyperlipidaemia reduces progression of the disease.47-50 Moreover, treatment of hypercholesterolaemia reduces complications of associated medical disorders such as coronary artery disease. The Lipid Research Clinics Trial revealed that for every reduction of 1 % in the serum cholesterol there is also a 2% reduction in mortality from coronary artery disease.sl,s2.
A fractionation into the lipoproteins should be obtained in patients with elevated cholesterol. In such patients the goal of antilipid therapy should be a serum cholesterol level of less than 200mg/dl (5.1mmol/L) or an LDL cholesterol value of less than 120mg/dl (3.lmmol/L). In patients with modest elevations of serum cholesterol, treatment should begin with a low-cholesterol diet. It is helpful to enlist the aid of a nutritionist as well as the patient's family to increase the chances that such a diet will be initiated and maintaineda family conference with the nutritionist is more likely to be successful than a simple admonition from the physician. Adherence to a low-cholesterol diet can reduce values by 10-15%. If after three months of diet the cholesterol is not sufficiently reduced, or if the serum cholesterol is more than moderately elevated at the first visit, drug therapy is initiated. Several forms of pharmacological intervention are available. Nicotinic acid is the least expensive agent and has the longest track record. A dose of 250mg three times daily with meals is used to initiate therapy, and this may be increased up to a maximal dose of 2g three times daily in order to achieve the target cholesterol value. The most common side effects are flushing, hypotension and gastric upset, but these can be reduced by prescribing one aspirin 30-60 minutes prior to the dose of nicotinic acid, which should be taken with a meal. Side effects can also be reduced by beginning at a low dose and gradually increasing it to achieve the desired effect. Another form of therapy includes the cholesterol-binding resins, such as cholestyramine or colestipol. These are effective agents but are less well tolerated, primarily due to gastrointestinal side effects. In patients with hypertriglyceridaemia and hypercholesterolaemia, weight reduction and avoidance of free sugar and alcohol is the first step in therapy. Such patients benefit from gemfibrozil, which will reduce both serum cholesterol and triglyceride levels. A dose of 300mg twice daily is used to initiate therapy and can be increased up to 600mg three times daily.
Inhibitors of HMG co-A reductase can be utilized. These agents are usually very well tolerated, are efficacious and can generally be given once daily; although action is improved when given at night. The initial dose of lovastatin is 20mg daily -this can be increased to a maximum of 80mg daily in two divided doses. In patients resistant to single drug therapy and diet, combinations of these agents may be employed; the combination of nicotinic acid and an HMG co-A reductase inhibitor is often effective in these patients.
All these lipid-lowering drugs frequently induce disturbances of liver serum chemistries. A twoto threefold elevation in hepatic enzymes may be observed, and the drug should be reduced or discontinued if hepatic enzyme levels continue to risethis will usually result in a normalization of these values. In rare cases, bone marrow suppression may be induced by some of these agents and serum chemistries and complete blood counts should therefore be obtained from these patients at periodic intervals (e.g. every three months) and more frequently when therapy is initiated. A slightly increased incidence of lens opacities has been observed in patients treated with inhibitors of HMG co-A reductase, so it is advisable to obtain a slit lamp examination prior to initiating therapy and at intervals of 6-12 months thereafter until more experience is gained with these agents.
Another agent which may prove to be of benefit in hypercholesterolaemia is eicosapentaenoic acid. This polyunsaturated fatty acid is believed to be responsible for the beneficial effect of fish oil in reducing cardiovascular events. Populations consuming large amounts of marine lipids (such as the Greenland Eskimos) have lower rates of cardiovascular disease. 53, 54 The beneficial effect of fish oil may be due to its salutory influence on plasma lipid levels, its effect on reducing platelet aggregability and/or a direct effect in improving endothelial function. 55-59 Whatever the mechanism, evidence suggests that fish oil inhibits the progression of atherosclerosis, 60 and patients should therefore be encouraged to substitute fish for other sources of protein -fish oil supplements may also be considered. High doses of eicosapentaenoic acid (lOg/day) are required to demonstrate an effect on platelet function equivalent to one aspirin daily,.58 Whether such high doses are required to retard atherosclerosis in man has not been determined.
Treatment of hypertension
Hypertension is another risk factor which demands the attention of the physician. Treatment of hypertension is known to prevent complications of associated medical disorders such as stroke and possibly myocardial infarction,61-63 but clinical trials to investigate whether treatment alters the natural history of peripheral arterial occlusive disease have not been performed. The drug therapy selected for the control of blood pressure depends on associated medical conditions such as pulmonary disease, diabetes mellitus or coexistent angina. In the past, beta-adrenergic antagonists have been avoided in patients with arterial occlusive disease, but more recent studies have shown no reduction in calf blood flow or in walking distance during therapy with these agents in patients with intermittent claudication. 64 Although vasodilators have not been shown to be effective in increasing blood flow to the claudicating limb, there is recent evidence that some of these agents may reduce the progression of atherosclerosis. 65 Results showing that calcium channel blockers preserve endothelial function and retard atherosclerosis in animal models have led to the initiation of a number of clinical trials to assess the effect of these agents on the progression of atherosclerosis in man, the results of which are eagerly awaited.
Treatment of diabetes mellitus
Diabetes mellitus is another risk factor for arterial occlusive disease and is associated with an adverse prognosis in these patients. Patients with diabetes mellitus are more likely to have progression of disease, failure of bypass grafts, complications of associated medical disorders such as myocardial infarction and stroke6,68,69 and are more likely to present with claudication in association with diffuse infrapopliteal disease which is not amenable to surgical therapy.70,71 Because strict control of hyperglycaemia has been shown to reduce the incidence of some microvascular complications (such as renal glomerulosclerosis) and reduce basement membrane thickening, close monitoring and control of hyperglycaemia seems warranted in these patients, even though a clinical trial has not yet been performed to substantiate this approach in patients with claudication. 72, 73 Family history A family history of premature arterial occlusive disease increases the risk of developing the complications of premature atherosclerosis. For this reason, subjects with a family history should have more aggressive treatment of their other risk factors. In those with a very high incidence of premature arterial occlusive disease in their relatives it may be reasonable to search for an underlying lipid disorder, coagulopathy, autoimmune disease or homocystinuria. Methionine tolerance can be demonstrated in as many as 30% of patients with premature peripheral and cerebrovascular artery disease, suggesting heterozygosity for homocystinuria.74 Antithrombotic therapy Although aspirin has not been shown to prevent the progression or complications of peripheral arterial occlusive disease, there is a wealth of evidence demonstrating a beneficial effect in other circulations. The Physician's Health Study revealed that a dose of 325mg aspirin every second day reduced the risk of myocardial infarction by 44%.~5 One aspirin three times daily improves graft patency following aortocoronary saphenous vein bypass grafting.76 It therefore seems reasonable to prescribe one aspirin daily for these patients, if only to reduce the likelihood of complications from arterial occlusive disease in other circulations. Sulfinpyrazone and dipyridamole have also been used as antiplatelet agents, but seem to have no greater efficacy when combined with aspirin than aspirin alone. 77 Eicosapentaenoic acid, which is found in high quantities in fish oil, is also an antiplatelet agent.56,58 Its effects can be seen in Greenland Eskimos, who consume large quantities of marine lipids and have an increased bleeding time and a reduced incidence of atherosclerosis. 54-56 The beneficial effect of eicosapentaenoic acid is in part due to its competition with arachidonic acid for the cyclo-oxygenase pathway. 58 It is converted into PG13 (a prostacyclin-like compound) or to thromboxane A3 (which is structurally similar to thromboxane A2 but inactive). Thus, fish oil favours a change in balance in the arachidonic acid pathway towards production of vasodilator/anti-aggregant substances than vasoconstrictor/platelet-aggregating substances.
Other antithrombotic therapies such as coumadin or heparin both have theoretical benefits, but have not been shown to reduce the progression or complications of arterial occlusive disease. The chronic use of coumadin is probably not justifiable in these patients because of its lack of a proven beneficial effect and because its use can be complicated by significant haemorrhagic events.
Vasodilator therapy
Drugs whose principal action is to dilate either large conduit arteries or resistance vessels are ineffective in treating patients with intermittent claudication. Aspects of the pathophysiology of leg claudication may explain why vasodilator drug therapy does not improve symptoms. As a consequence of a critical atherosclerotic stenosis, distal perfusion pressure is reduced. Normally, intramuscular arterioles dilate in response to the metabolic demands of exercise, and blood flow subsequently increases to the exercise extremity. In patients with stenotic lesions, blood flow augmentation is blunted and distal perfusion pressure falls during exercise, resulting in the accumulation of metabolites. These substances potentiate vasodilation and cause perfusion pressure to fall further. The extravascular compressive force caused by the exercising muscle results in the virtual collapse of the resistance vessels. Thus, vasodilator drugs are unlikely to cause any favourable effects in the vasculature distal to a critical stenosis, they may redistribute blood flow to unaffected areas and, theoretically, they may worsen the symptoms of claudication. Many vasodilator drugs, such as alpha-adrenergic antagonists (reserpine, guanethidine), beta-adrenoceptor agonists (isoproterenol, nylidrin), calcium channel blockers (nifedipine) and direct smooth muscle relaxants (nitrates, nicotinic acid) have been evaluated in clinical trials. None of these agents has been shown to improve blood flow to an exercising extremity in a patient with significant atherosclerosis or to improve symptoms of intermittent claudication.~ge9
Vasodilator drugs might be effective if they augmented flow through collateral vessels. Ketanserin, a serotonin (S2) antagonist, has been shown to increase collateral blood supply in patients with peripheral arterial occlusive disease.g~ This drug was studied in a multicentre trial involving patients with intermittent claudication.g1~82 Compared to placebo, ketanserin did not improve treadmill exercise time in patients with intermittent claudication.
Haemorheologic drugs
Another theoretical approach to improving blood supply in patients with peripheral arterosclerosis is to administer drugs which have a favourable effect on blood rheology. Such drugs may reduce red cell deformability or improve blood viscosity. Pentoxifylline is one such agent which has been shown to improve walking capacity in patients with intermittent claudication,83--88 although not all patients experience the salutary effects of this drug and many experience nausea or dizziness.
Summary
Occlusive atherosclerotic disease of the extremity is a problem frequently seen by the physician and one which is most prevalent in older individuals. The prognosis of patients with this disorder is related primarily to coexistent coronary artery and cerebrovascular disease. A careful history and physical examination is usually sufficient to establish the diagnosis. Noninvasive vascular testing establishes the severity of the disease objectively and provides a means of assessing progression of the disease. Medical management is employed in most patients who have stable symptoms of claudication. Such management focuses attention on atherosclerotic risk factors and includes cessation of tobacco use, control of hypercholesterolaemia, and careful management of diabetes mellitus. Pharmacological treatment either with antithrombotic or vasodilator drugs is not effective in treating patients with claudication, but drugs which improve blood rheology may be helpful in selected circumstances. Revascularization procedures are generally reserved for those patients whose disability severely affects their lifestyle or occupation, for those with symptoms or signs of ischaemia at rest and for those whose limbs are in jeopardy.
